BR112014013565A2 - variante da opn para uso no tratamento ou prevenção de câncer envolvendo pelo menos um tumor canceroso, método de tratamento ou prevenção do câncer, composição farmacêutica e suplemento nutricional - Google Patents

variante da opn para uso no tratamento ou prevenção de câncer envolvendo pelo menos um tumor canceroso, método de tratamento ou prevenção do câncer, composição farmacêutica e suplemento nutricional

Info

Publication number
BR112014013565A2
BR112014013565A2 BR112014013565A BR112014013565A BR112014013565A2 BR 112014013565 A2 BR112014013565 A2 BR 112014013565A2 BR 112014013565 A BR112014013565 A BR 112014013565A BR 112014013565 A BR112014013565 A BR 112014013565A BR 112014013565 A2 BR112014013565 A2 BR 112014013565A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
prevention
pharmaceutical composition
nutritional supplement
cancerous tumor
Prior art date
Application number
BR112014013565A
Other languages
English (en)
Portuguese (pt)
Inventor
Serena Anja
Langborg Wejse Peter
R Rittling Susan
Original Assignee
Arla Foods Amba
Forsyth Dental Infirmary For Children (D B A The Forsyth Institute)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods Amba, Forsyth Dental Infirmary For Children (D B A The Forsyth Institute) filed Critical Arla Foods Amba
Publication of BR112014013565A2 publication Critical patent/BR112014013565A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014013565A 2011-12-07 2012-12-07 variante da opn para uso no tratamento ou prevenção de câncer envolvendo pelo menos um tumor canceroso, método de tratamento ou prevenção do câncer, composição farmacêutica e suplemento nutricional BR112014013565A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161567899P 2011-12-07 2011-12-07
US201261673912P 2012-07-20 2012-07-20
EP12177329 2012-07-20
PCT/US2012/068628 WO2013086459A1 (en) 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Publications (1)

Publication Number Publication Date
BR112014013565A2 true BR112014013565A2 (pt) 2019-09-24

Family

ID=48574961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013565A BR112014013565A2 (pt) 2011-12-07 2012-12-07 variante da opn para uso no tratamento ou prevenção de câncer envolvendo pelo menos um tumor canceroso, método de tratamento ou prevenção do câncer, composição farmacêutica e suplemento nutricional

Country Status (12)

Country Link
US (1) US20150344534A1 (https=)
EP (1) EP2788015A1 (https=)
JP (1) JP2015500836A (https=)
KR (1) KR20140104474A (https=)
CN (1) CN104080472A (https=)
AR (1) AR089136A1 (https=)
AU (1) AU2012347468A1 (https=)
BR (1) BR112014013565A2 (https=)
CA (1) CA2858379A1 (https=)
EA (1) EA201491010A1 (https=)
WO (1) WO2013086459A1 (https=)
ZA (1) ZA201404920B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656474T3 (es) 2013-07-05 2018-02-27 Arla Foods Amba Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
IL106576A (en) * 1992-08-13 2000-08-13 Immunotec Res Corp Ltd Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer
IL145891A0 (en) * 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
US7259243B2 (en) * 2000-01-07 2007-08-21 Arla Foods Amba Process for isolation of osteopontin from milk
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
JP4509114B2 (ja) * 2003-09-18 2010-07-21 アルラ・フーズ・エイ・エム・ビィ・エイ 幼児用調製乳
SM200600031B (it) * 2006-10-06 2009-05-11 Gianluca Mech Integratore alimentare con attivatore proteico
ES2538362T3 (es) * 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C

Also Published As

Publication number Publication date
EA201491010A1 (ru) 2015-01-30
AR089136A1 (es) 2014-07-30
EP2788015A1 (en) 2014-10-15
WO2013086459A1 (en) 2013-06-13
KR20140104474A (ko) 2014-08-28
AU2012347468A1 (en) 2014-06-26
ZA201404920B (en) 2015-12-23
US20150344534A1 (en) 2015-12-03
CA2858379A1 (en) 2013-06-13
CN104080472A (zh) 2014-10-01
JP2015500836A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
IL285474A (en) Anti- pdl1 antibody compositions
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112013011480A8 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
SI2986304T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
HK1216853A1 (zh) 治療胰腺癌的方法
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
CL2015001250A1 (es) Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
BR112013019083A2 (pt) combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
BRPI0920847A2 (pt) composto, formulação farmacêutica, e, método para o tratamento, prevenção ou retardo na progressão de câncer em um paciente
CL2015001818A1 (es) Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.